Clinicopathologic features with collecting duct carcinoma of kidney: report of 10 cases
10.3760/cma.j.issn.0529-5807.2018.02.009
- VernacularTitle: 肾集合管癌十例临床病理分析
- Author:
Jinxing ZHOU
1
;
Xiaorong HE
;
Guoxin SONG
;
Zigui ZOU
;
Luhua WANG
;
Ran HU
;
Hongxia LI
Author Information
1. Department of Pathology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
- Publication Type:Journal Article
- Keywords:
Kidney tubules, collecting;
Pathology, clinical;
Immunophenotyping;
Diagnosis, differential;
Prognosis
- From:
Chinese Journal of Pathology
2018;47(2):123-127
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the pathological features, immunophenotypes, differential diagnoses and prognostic parameters of collecting duct carcinoma of the kidney (CDC).
Methods:Clinical imaging, histopathology, immunohistochemistry, and survival data of 10 patients at First Affiliated Hospital of Nanjing Medical University from January 2009 to August 2017 were retrospectively analyzed along with a review of literatures.
Results:The clinical symptoms of CDC were not specific, and image examinations showed space-occupying mass lesions. Tumors were mainly located in renal medulla with grey and firm cut face and the presence of focal hemorrhage and necrosis. Microscopically, there were predominant tubular or tubular-papillary structures with associated focal sarcomatoid areas, desmoplastic stromal reaction and lymphoplasmacytic cells infiltration. Tumor cells had marked cytological atypia with high grade nuclei, conspicuous nucleolus and numerous mitoses. Immunohistochemically, tumor cells were strongly positive for CK19, E-cadherin, vimentin, HCK, CK7 and PAX8. The main treatment was radical nephrectomy in the patients. Seven cases died of CDC with median survival of 10 months.
Conclusions:CDC is a rare, highly aggressive malignancy of kidney with poor prognosis. Definitive diagnosis should be made by histology and immunohistochemistry. Differential diagnoses include papillary renal cell carcinoma(type Ⅱ), renal medullary carcinoma, infiltrating high grade urothelial carcinoma, renal pelvis adenocarcinoma and metastatic adenocarcinomas.
